Semaglutide

司美格鲁肽

Report date: 2026/05/20 20:02:01

Base Information

Drug NameSemaglutide
Drug Alias Namesemaglutida索马鲁肽索玛鲁肽semaglutidum司美鲁肽 +[24] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsRejection of renal transplantationChemotherapy induced poisoningCoronavirus Disease 2019 (COVID-19) +[72] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryUnited States
Original Approved Date2017/12/05
Country/TerritoryFormer Serbia and MontenegroCzechiaBelgium +[61] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesNovo Nordisk Pharma LtdGilead Inc +[53] 
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)University of TorontoVirginia Commonwealth University +[5] 
Active IndicationsRejection of renal transplantationChemotherapy induced poisoningIschemic Stroke +[62] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Cognitive DysfunctionMental Disorders +[10] 

Other Information

ATC CodeA10BJ06
Related LinksWikipediaDrugBankKEGG